Product Images Bortezomib

This appears to be a medical study or clinical trial involving the use of Bortezomib and Dexamethasone in patients. The study includes statistical analysis with p-values and the number of patients remaining at specific time points. It seems to be evaluating the effectiveness of these medications in treating a certain condition.*

This text appears to show data related to a medical study or clinical trial, with information on hazard ratios and subjects at risk over a specified time period. The study involves two treatment groups - VeR-CAP and R-CHOP. The timeline spans from 0 to 108 months from randomization, with corresponding numbers of subjects at each time point for both treatment groups. The hazard ratio provided is 0.66 with an 85% confidence interval of 0.51 to 0.85. The data suggests that the study is evaluating the effectiveness or outcomes of VeR-CAP and R-CHOP treatments over time.*

This text appears to be a description of a medication containing bortezomib. It includes information on the contents, recommended dosage, storage instructions, and manufacturing details. The medication is for intravenous use only and is described as a hazardous agent. It is stored in a refrigerator between 2°C and 8°C. The text also mentions the manufacturer's license number, LOT number, and expiration date.*

This is a description of a pharmaceutical product called Bortezomib Injection, which is intended for intravenous use only. The product is a hazardous agent and comes in a 1 mL single-dose vial. The recommended dosage and dilution information are provided in the text. It is important to store the product in a refrigerator between 2°C to 8°C to maintain its efficacy. Unused portions should be discarded properly.*

This text provides instructions for preparing a Bortezomib Injection with a concentration of 2.5 mg/mL. It suggests diluting the injection with 1.5 mL of 0.9% Sodium Chloride Injection, USP to achieve a final concentration of 1 mg/mL. This manual process is detailed and should be followed per the Prescribing Information for accurate results.*

The text describes a medication with the active ingredient Bortezomib, which is used for injection. It provides details on the contents of each mL, the recommended dosage, storage instructions, and prescription information. The medication is designated as a hazardous agent and should be stored in a refrigerator. Additional details include the lot number and expiration date.*

This is a pharmaceutical label providing information about Bortezomib Injection, including dosage, dilution instructions, and storage conditions. It contains details such as the drug concentration, administration route (intravenous), and precautions regarding hazardous materials. The label also specifies the need to discard any unused portion of the medication and to dilute it with Sodium Chloride Injection. Storage instructions recommend refrigeration within a specific temperature range to maintain efficacy. For more precise usage details, it advises consulting prescribing information.*

This is a description for an intravenous injection of Bortezomib, with a concentration of 3.5 mg/1.4 mL. It needs to be diluted with 2.1 mL of 0.9% Sodium Chloride Injection, USP to reach a final concentration of 1 mg/mL. The process involves a total of 24 mL of 0.9% Sodium Chloride Injection, USP to achieve the desired concentration. Additional instructions including placing a sticker on the syringe and referring to the prescribing information for full details.*